title: Treatment of hemiplegic migraine with triptans.
abstract: The objective of this study was to investigate the efficacy, safety and tolerability of triptans in patients who suffer from familial or sporadic hemiplegic migraine. Seventy-six subjects had used triptans at least once as an abortive treatment. Average triptan response was 6.9 (SD +/-3.1) and adverse event severity 4.9 (SD +/-3.3) on a scale from 0 to 10 (no response or side effect 0, excellent response or unbearable side effects 10). None of the patients had an ischaemic stroke or a heart attack. One patient reported prolonged neurological symptoms, related to a single dose of rizatriptan, but there were no pathological findings in several MRI-scans. Triptans seem to be safe and effective treatment for most hemiplegic migraine patients.
authors: Department of Neurology, Helsinki University Central Hospital, Finland. ville.artto@hus.fi
authors: V
authors: V
authors: Artto
authors: M
authors: M
authors: Nissilä
authors: M
authors: M
authors: Wessman
authors: A
authors: A
authors: Palotie
authors: M
authors: M
authors: Färkkilä
authors: M
authors: M
authors: Kallela
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020325:Migraine with Aura / Q000188:drug therapy*; D009460:Neurologic Examination; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014363:Tryptamines / Q000627:therapeutic use*
chemical_list: D017366:Serotonin Receptor Agonists; D014363:Tryptamines